Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant aminopeptidase A (rAPA) is a recombinant form of the enzyme aminopeptidase A (APA, also known as glutamyl aminopeptidase or ENPEP). APA is a membrane-bound zinc metallopeptidase that plays a key role in the renin-angiotensin system (RAS) by cleaving the N-terminal aspartate residue from various angiotensin peptides, including angiotensin II (Ang II), angiotensin I (Ang I), and angiotensin-(1-12). By degrading these pro-hypertensive peptides, rAPA reduces their pressor effects and mitigates acute systolic blood pressure elevation. It is being investigated as a potential therapeutic approach for the treatment of hypertension resulting from RAS overactivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on recombinant aminopeptidase A.